NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is a publicly traded Healthcare sector company. As of May 21, 2026, NAMS trades at $35.77 with a market cap of $3.99B and a P/E ratio of -20.07. NAMS moved +6.11% today. Year to date, NAMS is +6.78%; over the trailing twelve months it is +84.75%. Its 52-week range spans $14.06 to $42.21. Analyst consensus is strong buy with an average price target of $48.00. Rallies surfaces NAMS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes NAMS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $35.77 |
| Market Cap | $3.99B |
| P/E Ratio | -20.07 |
| EPS | $-1.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $42.21 |
| 52-Week Low | $14.06 |
| Volume | 1.15M |
| Avg Volume | 0 |
| Revenue (TTM) | $22.57M |
| Net Income | $-212.73M |
| Gross Margin | 0.00% |
11 analysts cover NAMS: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $48.00.